Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 9:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dasatinib + Quercetin Clear all
Enrolling by invitation Phase 2 Interventional

Senescence in Chronic Kidney Disease

NCT02848131
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Group 2: Dasatinib, Group 2: Quercetin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 23, 2026, 9:18 AM EDT
Completed Phase 2 Interventional

Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study

NCT07000734
View directory record Official record
Conditions
Aging, Cognitive Decline, Older Adults, Cardiovascular, Sedentary Behaviors, Immune Senescence, Motor Function
Interventions
Risk managment, Dasatinib, Quercetin (dietary supplement), Vortioxetine
Behavioral · Drug · Dietary Supplement
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 23, 2026, 9:18 AM EDT
Recruiting Phase 2 Interventional

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

NCT06940297
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Ciltacabtagene Autoleucel, Computed Tomography, Cyclophosphamide, Dasatinib, Fludarabine, Positron Emission Tomography, Quercetin
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 23, 2026, 9:18 AM EDT
Completed Phase 2 Interventional

Improving Physical Ability and Cellular Senescence Elimination in HIV

NCT07144293
View directory record Official record
Conditions
HIV, Frailty, Prefrail, Aging Problems
Interventions
Dasatinib, Quercetin, Placebo - Dasatinib, Placebo - Quercetin
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
50 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
24
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 23, 2026, 9:18 AM EDT
Completed Phase 1 Interventional

Hematopoietic Stem Cell Transplant Survivors Study

NCT02652052
View directory record Official record
Conditions
Stem Cell Transplant
Interventions
Standard of Care - Observation Only, Group 2: Quercetin, Group 2: Dasatinib
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 23, 2026, 9:18 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer

NCT04733534
View directory record Official record
Conditions
Frailty, Childhood Cancer
Interventions
Dasatinib plus Quercetin, Fisetin
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 23, 2026, 9:18 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging

NCT04946383
View directory record Official record
Conditions
Aging
Interventions
Dasatinib plus Quercetin
Drug
Lead sponsor
TruDiagnostic
Industry
Eligibility
40 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Sep 23, 2026, 9:18 AM EDT
Active, not recruiting Phase 2 Interventional

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study

NCT04685590
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Interventions
Dasatinib + Quercetin, Placebo Capsules
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 23, 2026, 9:18 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

ALSENLITE: Senolytics for Alzheimer's Disease

NCT04785300
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Dasatinib, Quercetin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 23, 2026, 9:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans

NCT04313634
View directory record Official record
Conditions
Healthy
Interventions
Dasatinib, Quercetin, Fisetin
Drug
Lead sponsor
Sundeep Khosla, M.D.
Other
Eligibility
60 Years and older · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Sep 23, 2026, 9:18 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects

NCT05653258
View directory record Official record
Conditions
Obesity, Healthy Lifestyle
Interventions
Lifestyle Intervention, Dasatinib 100 MG, Quercetin 1000mg, Placebo, Abdominal adipose tissue biopsy
Other · Drug · Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 23, 2026, 9:18 AM EDT
Recruiting Early Phase 1 Interventional

Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease

NCT07025226
View directory record Official record
Conditions
Glioma
Interventions
Biospecimen Collection, Dasatinib, Fisetin, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography, Quercetin, Temozolomide, Topoisomerase-1 Inhibitor LMP744, Single Agent Therapy
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 23, 2026, 9:18 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease

NCT05422885
View directory record Official record
Conditions
Aging
Interventions
Dasatinib, Quercetin
Drug
Lead sponsor
Lewis Lipsitz
Other
Eligibility
65 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 23, 2026, 9:18 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Senolytic Therapy to Modulate Progression of Alzheimer's Disease

NCT04063124
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Dasatinib + Quercetin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Sep 23, 2026, 9:18 AM EDT
Active, not recruiting Phase 2 Interventional

Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

NCT05838560
View directory record Official record
Conditions
Schizophrenia, Treatment Resistant Depression, Aging, Premature
Interventions
Dasatinib, quercetin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 23, 2026, 9:18 AM EDT
Completed Phase 1 Interventional

Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial

NCT02874989
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Dasatinib + Quercetin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Winston-Salem, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 23, 2026, 9:18 AM EDT
Not yet recruiting Phase 1 Interventional

Senolytics for Secondary Progressive MS

NCT07270120
View directory record Official record
Conditions
Multiple Sclerosis (MS) Secondary Progressive
Interventions
Dasatinib and quercetin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 23, 2026, 9:18 AM EDT